As a consequence of the transfer of its Jyseleca® business to Alfasigma, the revenues and costs related to Jyseleca® for the full years 2024 and 2023 are presented separately from the results of the ...
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma ...
Researchers observed an increase in both CXCR4 and CD5 levels as the cells progressed to later stages of the cell cycle, particularly in the S/G2/M phases.
With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in the most cancer types. | With another trial win, Bristol Myers Squibb is ...
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...
An international study of over 800 chronic lymphocytic leukemia (CLL) patients found that an all-tablet therapy of ...
A study showed that using measurable residual disease (MRD) to guide ibrutinib-venetoclax therapy significantly improved ...
An international study published in the New England Journal of Medicine provides hope for chronic lymphocytic leukemia (CLL) ...
Financial GeoVax Anticipates Significant 2025 Progress With Catalyst-Rich Milestones Across Key Programs 05.02.2025 / 15:06 CET/CEST The issuer is solely responsible for the content of this ...
Chronic lymphocytic leukemia (CLL) is a B-cell malignancy, with disease progression ranging from slow and indolent to ...
During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed the data supporting the 2 newer BTK ...
Veterinarians were able to catch the ray's cancer early, allowing her to "thrive" and also allowing experts to collect data to treat the rare cancer in the future.